Langenbeck's Archives of Surgery

, Volume 398, Issue 1, pp 71–77 | Cite as

Liver transplantation for hilar cholangiocarcinoma—a single-centre experience

  • Silke Schüle
  • Annelore Altendorf-Hofmann
  • Frank Uteß
  • Falk Rauchfuß
  • Martin Freesmeyer
  • Thomas Knösel
  • Yves Dittmar
  • Utz Settmacher
Original Article

Abstract

Background

Cholangiocarcinoma is an infrequent malignancy, often unresectable at the time of diagnosis. Liver transplantation may offer a chance for cure, but results in the past have been disappointing, prompting transplant centres to adopt multimodal treatment protocols and extreme patient selection.

Purpose

This study was designed to evaluate the outcome of patients with irresectable hilar cholangiocarcinoma undergoing liver transplantation in order to determine criteria for patient selection.

Methods

We reviewed our prospective cancer registry for patients with hilar cholangiocarcinoma treated by transplantation since 1997. Data were evaluated regarding tumour location, stage, overall survival, recurrence rates and prognostic factors.

Results

Liver transplantation with lymphadenectomy was realised in 16 patients with hilar cholangiocarcinoma. Seven patients received a living donor graft. Lymph node metastases were found in eight patients with a median of 13 harvested nodes and had a statistically significant negative impact on overall survival irrespective of tumour size. Only one patient underwent neoadjuvant brachytherapy and developed fatal septic complications; 3- and 5-year survival rates were 63 and 50 % in lymph node-negative patients without neoadjuvant treatment.

Conclusions

Acceptable survival rates can be achieved by transplantation for hilar cholangiocarcinoma with lymph node metastases as the only exclusion criterion. We recommend staging laparotomy with lymphadenectomy along the common hepatic artery prior to liver transplantation.

Keywords

Hilar Cholangiocarcinoma Liver transplantation Multimodal therapy Prognosis 

References

  1. 1.
    Akamatsu N, Sugawara Y, Hashimoto D (2011) Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol 2(2):94–107. doi:10.5306/wjco.v2.i2.94 PubMedCrossRefGoogle Scholar
  2. 2.
    Schule S, Altendorf-Hofmann AK, Knosel T, Utess F, Settmacher U (2012) Diagnostic procedures and results in surgical therapy for cholangiocarcinoma. Zentralbl Chir. doi:10.1055/s-0031-1283831
  3. 3.
    Rosen CB, Heimbach JK, Gores GJ (2010) Liver transplantation for cholangiocarcinoma. Transpl Int 23(7):692–697. doi:10.1111/j.1432-2277.2010.01108.x PubMedCrossRefGoogle Scholar
  4. 4.
    Schnitzbauer AA, Schlitt HJ, Geissler EK (2011) Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Transplantation 91(11):1173–1176. doi:10.1097/TP.0b013e318215e72b PubMedCrossRefGoogle Scholar
  5. 5.
    Kaiser GM, Sotiropoulos GC, Jauch KW, Lohe F, Hirner A, Kalff JC, Konigsrainer A, Steurer W, Senninger N, Brockmann JG, Schlitt HJ, Zulke C, Buchler MW, Schemmer P, Settmacher U, Hauss J, Lippert H, Hopt UT, Otto G, Heiss MM, Bechstein WO, Timm S, Klar E, Holscher AH, Rogiers X, Stangl M, Hohenberger W, Muller V, Molmenti EP, Fouzas I, Erhard J, Malago M, Paul A, Broelsch CE, Lang H (2008) Liver transplantation for hilar cholangiocarcinoma: a German survey. Transplant Proc 40(9):3191–3193. doi:10.1016/j.transproceed.2008.08.039 PubMedCrossRefGoogle Scholar
  6. 6.
    Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, Finn R, Durazo FA, Saab S, Tong MJ, Hiatt JR, Busuttil RW (2011) Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 146(6):683–689. doi:10.1001/archsurg.2011.116 PubMedCrossRefGoogle Scholar
  7. 7.
    Friman S, Foss A, Isoniemi H, Olausson M, Hockerstedt K, Yamamoto S, Karlsen TH, Rizell M, Ericzon BG (2011) Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol 46(3):370–375. doi:10.3109/00365521.2010.533384 PubMedCrossRefGoogle Scholar
  8. 8.
    Robles R, Figueras J, Turrion VS, Margarit C, Moya A, Varo E, Calleja J, Valdivieso A, Valdecasas JC, Lopez P, Gomez M, de Vicente E, Loinaz C, Santoyo J, Fleitas M, Bernardos A, Llado L, Ramirez P, Bueno FS, Jaurrieta E, Parrilla P (2004) Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 239(2):265–271. doi:10.1097/01.sla.0000108702.45715.81 PubMedCrossRefGoogle Scholar
  9. 9.
    Sotiropoulos GC, Kaiser GM, Lang H, Molmenti EP, Beckebaum S, Fouzas I, Sgourakis G, Radtke A, Bockhorn M, Nadalin S, Treckmann J, Niebel W, Baba HA, Broelsch CE, Paul A (2008) Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. Transplant Proc 40(9):3194–3195. doi:10.1016/j.transproceed.2008.08.053 PubMedCrossRefGoogle Scholar
  10. 10.
    Gu J, Bai J, Shi X, Zhou J, Qiu Y, Wu Y, Jiang C, Sun X, Xu F, Zhang Y, Ding Y (2012) Efficacy and safety of liver transplantation for patients with cholangiocarcinoma: a systematic review and meta-analysis. Int J Cancer. doi:10.1002/ijc.26019
  11. 11.
    Becker NS, Rodriguez JA, Barshes NR, O’Mahony CA, Goss JA, Aloia TA (2008) Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 12(1):117–122. doi:10.1007/s11605-007-0335-4 PubMedCrossRefGoogle Scholar
  12. 12.
    Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, Nyberg SL, Ishitani MB, Rosen CB (2006) Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 82(12):1703–1707. doi:10.1097/01.tp.0000253551.43583.d1 PubMedCrossRefGoogle Scholar
  13. 13.
    Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malago M (2011) Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther 34(9):1063–1078. doi:10.1111/j.1365-2036.2011.04851.x PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Silke Schüle
    • 1
  • Annelore Altendorf-Hofmann
    • 1
  • Frank Uteß
    • 1
  • Falk Rauchfuß
    • 1
  • Martin Freesmeyer
    • 2
  • Thomas Knösel
    • 3
  • Yves Dittmar
    • 1
  • Utz Settmacher
    • 1
  1. 1.Department of General, Visceral and Vascular SurgeryUniversity of JenaJenaGermany
  2. 2.Department of Nuclear MedicineUniversity of JenaJenaGermany
  3. 3.Institute of PathologyUniversity of JenaJenaGermany

Personalised recommendations